Gel-Free Tools for Quick and Simple Screening of Anti-Topoisomerase 1 Compounds
Fecha
2023-04-27Autor
Keller, Josephine Geertsen
Petersen, Kamilla Vandsø
Mizielinski, Karol
Thiesen, Celine
Bjergbæk, Lotte
Reguera, Rosa M.
Pérez-Pertejo, Yolanda
Balaña-Fouce, Rafael
Trejo, Ángela
Masdeu Margalef, Carme
Knudsen, Birgitta R.
Tesauro, Cinzia
Metadatos
Mostrar el registro completo del ítem
Pharmaceuticals 16(5) : (2023) // Article ID 657
Resumen
With the increasing need for effective compounds against cancer or pathogen-borne diseases, the development of new tools to investigate the enzymatic activity of biomarkers is necessary. Among these biomarkers are DNA topoisomerases, which are key enzymes that modify DNA and regulate DNA topology during cellular processes. Over the years, libraries of natural and synthetic small-molecule compounds have been extensively investigated as potential anti-cancer, anti-bacterial, or anti-parasitic drugs targeting topoisomerases. However, the current tools for measuring the potential inhibition of topoisomerase activity are time consuming and not easily adaptable outside specialized laboratories. Here, we present rolling circle amplification-based methods that provide fast and easy readouts for screening of compounds against type 1 topoisomerases. Specific assays for the investigation of the potential inhibition of eukaryotic, viral, or bacterial type 1 topoisomerase activity were developed, using human topoisomerase 1, Leishmania donovani topoisomerase 1, monkeypox virus topoisomerase 1, and Mycobacterium smegmatis topoisomerase 1 as model enzymes. The presented tools proved to be sensitive and directly quantitative, paving the way for new diagnostic and drug screening protocols in research and clinical settings.
Colecciones
Excepto si se señala otra cosa, la licencia del ítem se describe como © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).